Syndrome News and Research

RSS

EpiCept provides update on corporate strategy, reports net loss of $4.5M for first-quarter 2010

EpiCept Corporation today announced operating and financial results for the three months ended March 31, 2010, and provided an update with respect to the Company's key business initiatives.

6 May 2010

Positive results from Phase 2 clinical study of LX1031 in IBS patients presented at DDW 2010

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, presented results from its positive Phase 2 clinical study with LX1031 in patients with non-constipating irritable bowel syndrome at Digestive Disease Week 2010 in New Orleans, Louisiana.

6 May 2010

Alnylam Pharmaceuticals reports consolidated financial results for first quarter 2010

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2010, and company highlights.

6 May 2010

TearScience completes $44.5 million Series C funding

TearScience, a privately-held medical device company, today announced the completion of $44.5 million of Series C funding from new investors Essex Woodlands Health Ventures, Investor Growth Capital and General Catalyst. The company's existing investors, De Novo Ventures, Spray Ventures and Quaker Bio Ventures completed the round. The funding will allow TearScience to commercialize its devices designed for use by eye care professionals to diagnose and treat the most common form of chronic dry eye disease.

5 May 2010

New data on Surfaxin LS presented at 2010 PAS Annual Meeting

Discovery Laboratories, Inc., announced that new data regarding Surfaxin LS (its novel, lyophilized KL4 surfactant dosage form) were presented at the 2010 Pediatric Academic Societies Annual Meeting. The two studies presented demonstrate that Surfaxin LS improves lung function and oxygenation while attenuating lung inflammation in the preterm lamb model of respiratory distress syndrome.

5 May 2010

Diets rich in whole grain reduce risk of obesity and other diseases related to metabolic syndrome

Evidence from observational studies indicates that diets rich in whole grain reduce risk of obesity and other diseases related to the metabolic syndrome e.g. type 2 diabetes and cardio-vascular disease. The mechanisms involved are only partially elucidated. Work within HEALTHGRAIN has revealed novel insights regarding some potential mechanisms.

5 May 2010

Targeted antibiotics provide safe, long-lasting improvement for IBS patients, says study

A targeted antibiotic provides effective and long-lasting relief of Irritable Bowel Syndrome symptoms, according to the results of two multisite Phase III clinical trials designed by Cedars-Sinai researchers. Rifaximin is the first drug treatment for IBS that relieves symptoms while it's being administered and continues to benefit patients after they stop taking the drug.

5 May 2010

Health IT Roundup: Many obstacles, much promise

The Boston Globe: There is a lingering "professional resistance to electronic records systems that computerization advocates say threatens the goals of the new health care overhaul law. These advocates argue that using computers to track what care patients receive, for instance, is vital to deciding what medications and treatments work best."

5 May 2010

Mayo Clinic researchers identify genetic variants in serotonin genes that impact IBS

Most people associate serotonin with brain neurology, but over 95 percent of the body's serotonin occurs in the gastrointestinal tract, which has a complex neuronal circuit that has been called "the second brain" of the body.

5 May 2010

Brain changes indicative of Fragile X syndrome take place early

Brain changes associated with the most common cause of mental retardation can be seen in magnetic resonance imaging (MRI) scans of children as young as one to three years old, according to a study by researchers at the University of North Carolina at Chapel Hill and Stanford University.

4 May 2010

Ocera Therapeutics presents Phase 2 proof-of-concept study results of AST-120 in non-constipating IBS

Ocera Therapeutics, Inc. presented results yesterday from a Phase 2 proof-of-concept study of AST-120 (spherical carbon adsorbent) in the treatment of patients with non-constipating Irritable Bowel Syndrome (IBS) at DDW, the annual meeting of the American Gastroenterological Association. Data showed that subjects treated with AST-120 responded in a consistent manner with reduction in pain better than placebo at week four and at week eight, the primary time point for analysis. The company plans to initiate a Phase 2b study evaluating AST-120 in non-constipating IBS.

4 May 2010

Boston Scientific commences enrollment in trial comparing SCS to spine reoperation in FBSS patients

Boston Scientific Corporation today announced the start of patient enrollment in the EVIDENCE Clinical Trial, which compares the therapeutic effectiveness and cost effectiveness of spinal cord stimulation (SCS) therapy to spine reoperation in patients with failed back surgery syndrome (FBSS). The first patient was enrolled by Joseph Buwembo, M.D. and Krishna Kumar, M.D., F.R.C.S.C., at Regina General Hospital in Regina, Saskatchewan, Canada.

4 May 2010

Doctors often treat IBS patients with narcotics: Researchers

Doctors often unnecessarily treat irritable bowel syndrome with narcotics, according to a study led by University of North Carolina at Chapel Hill researchers.

4 May 2010

Rush Center for Urban Health Equity to focus on disparities in heart and lung disease

Rush University Medical Center has been awarded a $10 million grant from the National Institutes of Health to establish the Rush Center for Urban Health Equity. The aim of the Center is to find ways to promote changes to eliminate the disparities in heart and lung disease affecting inner city residents, in particular those who are low-income persons of color.

4 May 2010

Depressive symptoms after ACS associated with vascular brain changes

A new study published in the current issue of Psychotherapy and Psychosmatics has examined brain activity after a heart attack.This study provides the first evidence that persistent depressive symptoms after acute coronary syndrome are associated with vascular brain changes.

4 May 2010

Array BioPharma reports 18.4M revenue for third-quarter fiscal 2010

Array BioPharma Inc. today reported financial results for the third quarter of fiscal 2010.

4 May 2010

Penwest Pharmaceuticals reports net income of $3.9 million for first-quarter 2010

Penwest Pharmaceuticals Co. today announced its financial results for the first quarter ended March 31, 2010. Compared with the first quarter of 2009, first quarter 2010 revenues increased sharply to $8.8 million, and operating expenses decreased by 20%. The Company had net income of $0.12 per share for the first quarter of 2010.

3 May 2010

Syndrome News and Research

EpiCept provides update on corporate strategy, reports net loss of $4.5M for first-quarter 2010

Positive results from Phase 2 clinical study of LX1031 in IBS patients presented at DDW 2010

Alnylam Pharmaceuticals reports consolidated financial results for first quarter 2010

TearScience completes $44.5 million Series C funding

New data on Surfaxin LS presented at 2010 PAS Annual Meeting

Diets rich in whole grain reduce risk of obesity and other diseases related to metabolic syndrome

Targeted antibiotics provide safe, long-lasting improvement for IBS patients, says study

Health IT Roundup: Many obstacles, much promise

Mayo Clinic researchers identify genetic variants in serotonin genes that impact IBS

Brain changes indicative of Fragile X syndrome take place early

Ocera Therapeutics presents Phase 2 proof-of-concept study results of AST-120 in non-constipating IBS

Boston Scientific commences enrollment in trial comparing SCS to spine reoperation in FBSS patients

Doctors often treat IBS patients with narcotics: Researchers

Rush Center for Urban Health Equity to focus on disparities in heart and lung disease

Depressive symptoms after ACS associated with vascular brain changes

Array BioPharma reports 18.4M revenue for third-quarter fiscal 2010

Penwest Pharmaceuticals reports net income of $3.9 million for first-quarter 2010

Sleep problems in children and adolescents with ASDs associated with daytime behaviors: Report

New classification of depressive subtypes of depression proposed

CAM use higher among children with GI symptoms: Study

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News